MediPharm Labs Initiates EU and UK Production of Cannabis Metered Dose Inhalers

LOS ANGELES- MediPharm Labs Corp. has commenced production of its cannabis metered dose inhalers for the European Union and United Kingdom markets. This initiative is part of an exclusive sales and distribution agreement with Blackpoint Limited, targeting the €834 million European medicinal cannabis market projected for 2024 .

The inhalers are manufactured under Good Manufacturing Practices (GMP) and deliver precise doses of cannabis active pharmaceutical ingredients (API) without combustion or heating. This format offers patients a smoke-free and vapor-free option, aiming to provide consistent and reliable outcomes.

David Pidduck, CEO of MediPharm Labs, stated, “We’re excited to expand our international portfolio and partner with Blackpoint to bring our innovative cannabis metered dose inhaler to the EU and United Kingdom. This smoke- and vapor-free format supports our mission to advance global access to pharma-grade cannabinoid wellness products.”

David Martinez, CEO of Blackpoint, added, “Working together with the highly capable team at MediPharm is exciting, and we look forward to introducing our novel and much-needed metered dose products for the benefit of the growing number of patients across the EU and United Kingdom.”

The agreement includes minimum purchase obligations to ensure a steady supply of the product in the designated markets. MediPharm Labs plans to launch the inhalers in Australia, the EU, and the UK during the third quarter of 2025.